The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on intravesical microwave hyperthermia with intravesical chemotherapy for superficial bladder cancer.
The guidance was considered for reassessment in January 2011 and it was concluded that NICE will not be updating this guidance at this stage. However, if you believe there is new evidence which should warrant a review of our guidance, please email email@example.com.
This procedure is used for early-stage bladder cancer, and may be used before or after surgery. Solutions of chemotherapeutic drugs are delivered into the bladder using a thin tube inserted through the urethra. At the same time, an antenna placed inside the bladder emits microwaves that heat up the bladder lining. The heating is intended to damage the cancer cells and enhance the effect of the chemotherapeutic drugs.
This type of heated chemotherapy cannot currently be specifically captured using OPCS-4.
At present this is captured using the following codes:
M49.4 Introduction of a therapeutic substance into bladder
X70-X71 Procurement of drugs for chemotherapy for neoplasm Bands 1-10 (depending on the cytotoxic drug used)
X72 Delivery of chemotherapy for neoplasm (the delivery code is for outpatients and day cases only)
Y53.2 Approach to organ under ultrasonic control (if used).
In addition an ICD-10 code from category C67. - Malignant neoplasm of bladder is assigned.
The NHS Classifications Service of NHS Connecting for Health is the central definitive source for clinical coding guidance and determines the coding standards associated with the classifications (OPCS-4 and ICD-10) to be used across the NHS. The NHS Classifications Service and NICE work collaboratively to ensure the most appropriate classification codes are provided. www.connectingforhealth.co.uk/clinicalcoding